We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Lga4.0
L. gasseri Research
Mostly mechanism / observational
15 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most L. gasseri studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2010–2026 with a typical study size of 87 participants.
Based on 15 studies · 1 meta-analysis · 6 RCTs · 764 total participants
Confidence
Moderate confidence
By outcome
Body weight & obesityAt best about 1 kg of body weight and a few cm² of visceral fat over 12 weeks, mostly from within-group comparisons, and reversing within weeks of stopping · 12 weeks
Mostly mechanism / observational10 studies
Visceral & abdominal fat
Mostly mechanism / observational7 studies
IBS & digestive symptoms
Too few graded studies2 studies
Glucose & metabolic
Too few graded studies2 studies
Adipose tissue inflammation
Too few graded studies2 studies
Blood lipids & fatty acids
Too few graded studies1 study
Steady research
4 studies in the last 5 years · Latest meta-analysis: 2012
201020182026
1RCTn=200 · medium study2023
In plain English: These data suggest that LG2055 suppresses the subjective symptoms of the common cold by activating pDCs and improving the host's immune system in healthy adults, especially in immune-weakened individuals (UMIN000049183).
Kobatake E et al. · Nutrients (2023)
Three participants discontinued the trial and six participants were excluded from the analysis, thus 191 participants (95 in the LG2055 group and 96 in the placebo group) were analyzed.
The LG2055 group showed a significantly higher ratio of "without symptoms" responses for runny nose, plugged nose, sneezing, sore throat, hoarseness, and chill than the placebo group.
Furthermore, a stratified analysis revealed that LG2055 intake enhanced CD86 and HLA-DR expression in the pDCs of the participants with low secretion rates of salivary secretory immunoglobulin A.
In plain English: These might be promising alternatives, in addition to many others that involve adequate intake of vitamins, minerals and bioactive compounds from food.
Morais AHA et al. · Nutrients (2020)
In this context, alternatives related to nutritional therapy might help to control the infection.
This narrative review proposes the importance and role of probiotics and diet as adjunct alternatives among the therapies available for the treatment of this new coronavirus.
These might be promising alternatives, in addition to many others that involve adequate intake of vitamins, minerals and bioactive compounds from food.
In plain English: These findings provide new insights into the function of paraprobiotic CP2305 in relieving mild climacteric symptoms in women.
Sawada D et al. · Nutrients (2022)
The percentage of women with symptom relief for the SMI total score was 75.0%, with 30 of 40 women in the CP2305 group, and 55.0%, with 22 of 40 women in the placebo group (p = 0.0594).
Assessment was based on the observation of climacteric symptoms with two validated questionnaires-the Simplified Menopausal Index (SMI) and the Greene Climacteric Scale (GCS).
The results showed that CP2305 provided significant relief in the SMI total score, SMI vasomotor score, SMI psychological score, GCS total score, GCS somatic score, and GCS vasomotor score compared to the placebo.
In plain English: All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com.
Athapaththu HAD et al. · Letters in applied microbiology (2026)
The evidence indicates that probiotic strains, particularly Lactobacillus gasseri and Bifidobacterium breve, are consistently associated with reductions in visceral fat, total body fat, waist circumference (WC), and body fat percentage, while effects on body weight and BMI remain modest.
For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints.
All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com.
In plain English: The one trial with a genuine between-group visceral fat difference — 21.6 cm² at the highest dose.
Kim J et al. · J Med Food (2018)
Visceral adipose tissue was significantly lower in the high-dose group versus placebo (P=0.038); the between-group difference after 12 weeks was -21.6 cm² (P=0.012)
Waist circumference fell significantly from baseline in both the low- and high-dose groups but not in placebo
Biochemical parameters were NOT significantly different among the groups
In plain English: The largest SBT2055 trial — but the numbers are within-group changes, there is no dose-response, and the effect faded four weeks after stopping.
Kadooka Y et al. · Br J Nutr (2013)
Abdominal visceral fat area at week 12 changed from BASELINE by -8.5% (95% CI -11.9, -5.1; P<0.01) at 10^7 CFU/g and -8.2% (95% CI -10.8, -5.7; P<0.01) at 10^6 CFU/g
These are within-group changes from baseline; the paper's contrast is that no parameter decreased significantly in the control group
NO dose-response: the 10-fold lower dose produced essentially the same result
In plain English: The original result — 4.6% less visceral fat and 1.1 kg of body weight — all measured as change from baseline within the active group.
Kadooka Y et al. · Eur J Clin Nutr (2010)
Abdominal visceral fat area decreased from BASELINE by 4.6% (-5.8 cm², 95% CI -10.0 to -1.7; P<0.01) and subcutaneous fat by 3.3% (-7.4 cm²)
Body weight fell 1.4% (-1.1 kg, 95% CI -1.5 to -0.7; P<0.001); BMI -0.4 kg/m²; waist -1.7 cm; hip -1.5 cm
No between-group statistical test for fat area is reported — the comparison offered is that none of these parameters decreased significantly in the control group
In plain English: Lower postprandial fatty acids — but from a sequential, non-randomised, within-subject design with no parallel placebo group.
Ogawa A et al. · Lipids Health Dis (2014)
Postprandial serum non-esterified fatty acids from 120 to 480 minutes, and the triglyceride level at 120 minutes, were significantly lower in the active period (P<0.05)
Fasting serum non-esterified fatty acid fell significantly at week 4 versus the control period (P<0.001)
DESIGN CAVEAT: single-blind, within-subject, repeated-measure. All 20 subjects took the control fermented milk FIRST for 4 weeks, then washed out, then took the active — there was no randomisation and no parallel placebo arm
In plain English: The null one: a slight weight reduction, but no significant difference between the groups.
Jung SP et al. · Korean J Fam Med (2013)
At 12 weeks a slight reduction in body weight was noted in the BNR17 group, but there were NO significant weight changes between groups
Waist and hip circumference decreases were more pronounced with BNR17, but the authors state there were no significant differences between the two groups
PubMed indexes this paper as a Journal Article only — it is NOT tagged as a Randomized Controlled Trial despite the title
In plain English: The internal contradiction: the same strain suppressed adipose inflammation in mice while leaving body weight and abdominal fat completely unchanged.
Ukibe K et al. · Br J Nutr (2015)
Body weight and abdominal fat weight were NOT altered by feeding the strain — directly at odds with the anti-obesity framing of the other mouse study
Macrophage population in adipose tissue was significantly reduced, as was the M1 (inflammatory) share of total macrophages
Ccl2, Ccr2 and Lep expression were down-regulated; Il6, Tnf and Nos2 tended to be down-regulated